Impact of Hepatitis C Virus Infection on Bone Mineral Density in Renal Transplant Recipients

Wen-Hung Huang1,3, Mei-Ching Yu2,3, Jeng-Yi Huang1,3, Ping-Chin Lai1,3

1 Department of Nephrology, Chang Gung Memorial Hospital, Linkou, Taiwan, R.O.C 2 Department of Paediatric Nephrology, Chang Gung Children’s Hospital, Linkou, Taiwan, R.O.C 3 Chang Gung University College of Medicine, Taoyuan, Taiwan, R.O.C

Abstract

Background: The average prevalence of hepatitis C virus (HCV) infection in renal transplant recipients is 10%. Studies of these patients with HCV infection usually focuses on long-term graft survival and patient survival. Studies of the correlation between HCV infection and bone mineral density (BMD) in renal transplant patients are limited. The aim of this study was to investigate whether HCV infection is a risk factor for BMD change during a short follow-up period.

Methods: Seventy-six renal transplant recipients underwent 2 separate dual-energy X-ray absorptiometry (DXA) scans during a mean period of 14 months. Fifteen patients were HCV infection. First bone mineral density (BMD) at the lumbar spine, hip, and femoral neck was determined using dual-energy X-ray absorptiometry (DXA) between September 2008 and March 2009. After that, 34 patients took alendronate sodium 70 mg per week. Subgroups risk factors analysis was also performed into with or without alendronate. Immunosuppressive agents, bisphosphonates, patient characteristics, and biochemical factors were analyzed to identify associations with BMD.

Results: After 14 months, in 76 patients, BMD of the lumbar spine had significantly increased (from 0.9 g/cm² to 0.92 g/cm², p<0.001), whereas BMD of the hip and femoral neck had not. Multiple linear regression analysis showed that HCV infection was negatively associated with BMD change in the lumbar spine (β = 0.247, 95% CI, –0.035 to –0.002; p = 0.028). Moreover, in subgroup analysis, among 42 patients without alendronate, multiple linear regression analysis showed HCV infection was a risk factor for adverse BMD change of the lumbar spine (β = 0.371, 95% CI, –0.043 to –0.003; p = 0.023).

Conclusion: HCV infection in renal transplant recipients was a negative risk factor for BMD change in the lumbar spine. Moreover, alendronate may be able to reverse the negative effect of HCV infection on bone in renal transplant recipients.

Introduction

The natural history of hepatitis C virus (HCV) infection after renal transplantation is not fully understood [1]. HCV infection is still highly prevalent among patients with end-stage renal disease (ESRD), including renal transplant (RT) recipients, despite the screening of blood products for HCV [1,2]. The prevalence of HCV infection in RT recipients ranges from 5% to 15% [3,4]. Kidney transplantation in the presence of HCV infection has adverse effects on long-term graft survival and patient survival [5–7]. In the general population, lower bone mineral density (BMD) has been associated with chronic liver disease, including chronic viral hepatitis [8], and the pathophysiological basis of this association remains unclear. It may include alterations in vitamin D metabolism, gonadal status, or chronic inflammation. A direct role for chronic HCV infection in the pathogenesis of osteoporosis is further supported by the observation that fracture risk decreased in HCV-monoinfected patients who underwent successful antiviral treatment [9]. In a study of patients infected with either hepatitis B or C, but not with HIV, the severity of osteoporosis was related to the severity of liver disease by concomitant histology, even among those without the evidence of cirrhosis [10]. However, HCV co-infection has been identified as an independent risk factor for subsequent fragility fracture in multiple cohorts of HIV-infected persons [11,12]. In previous studies [13,14], we found that renal transplant recipients with HCV infection had a higher prevalence of osteoporosis than patients without HCV infection. After a long period of renal transplantation, the detrimental effects of steroid and immunosuppressive agents on bone condition diminished. Short-term alendronate administration effectively improves BMD in these patients. To our knowledge, studies of the correlation between HCV infection and BMD in renal transplant patients are few. And the role of HCV infection on BMD in renal transplant patients with or without alendronate is unclear. The aim of this observational case-control study was to investigate whether HCV infection is a risk factor for BMD change during a short follow-up period.

Materials and Methods

This retrospective case-control study complied with the guidelines of the Declaration of Helsinki and was approved by
the Medical Ethics Committee of Chang Gung Memorial Hospital, a tertiary referral center located in the northern part of Taiwan. Institutional Review Board approval was obtained, and because the study involved retrospective review of existing data, informed consent from the patients was not required. In addition, all individuals’ information was securely protected (by delinking identifying information from the main data set) and available to investigators only. Furthermore, all the data were analyzed anonymously. On the other hand, if this study had involved retrospective review of existing data in addition to retrospective analysis of remaining biological samples, both Institutional Review Board approval and specific informed consent from all patients would have been required. The Institutional Review Board of Chang Gung Memorial Hospital has specifically waived the requirement for consent. All primary data were collected according to Strengthening the Reporting of Observational Studies in Epidemiology guidelines [15]. The form described above was referenced from the previous study [14] and Liu et al.’s publication [16].

Study Sample

In this retrospective designed study, initially, we randomly enrolled 84 patients undergone transplant at least 5 months previously and had received DXA to obtain BMD measurements of the lumbar spine (LS), left hip (H), and femoral neck (FN) between September 2008 and March 2009 [13]. Alendronate (alendronate sodium, 70 mg/tablet, 70 mg per week) was administered to the patients until osteoporosis was diagnosed. Bone condition was defined on the basis of the World Health Organization (WHO) criteria: a BMD value $>2.5$ standard deviations (SD, $T$ score) below the mean for young adults indicated osteoporosis, and a BMD value between 1.0 and 2.5 SDs below the mean indicated osteopenia. In previous study [14], use of alendronate was found to be associated with positive prognosis of bone condition in renal transplantation patients. From above conception, the patients were divided into two groups: with or without alendronate for subgroup analysis. Fasting blood levels of serum creatinine (Cr), blood urea nitrogen (BUN), calcium, inorganic phosphate, and uric acid were evaluated. The corrected calcium ($Ca^{2+}$-calcium) concentration was calculated using the following equation: $Ca^{2+}$ = serum calcium (mg/dL) $\times$[0.8 (4.0 · serum albumin (g/dL)]. The patients’ medical records were assessed for history of diabetes mellitus (DM); smoking frequency; alcohol intake; and hepatitis B virus (HBV), hepatitis C virus (HCV), and cytomegalovirus (CMV) infections. Then, 76 of the 84 patients (8 of the 84 patients were excluded–2 subjects had died, 2 had graft failure, and the initial BMD measurements of 4 patients were lost) received 2nd DXA to obtain BMD measurements and fasting blood tests after a mean period of 14 months. All doses of an immunosuppressive agent administered between the 2 BMD measurements were considered as the cumulative dose.

Precautions and Contraindications for Alendronate

The first DXA report was obtained between September 2008 and March 2009. Alendronate (70 mg per week) was administered to the patients with osteoporosis diagnosed based on this DXA report, unless 1 or more of the following conditions was present: bisphosphonate allergy; blood calcium $<8$ mg/dL; active stomach problems (e.g., esophagitis, gastritis, or ulcers); renal insufficiency (estimated glomerular filtration rate [eGFR] $<30$ mL/[min·1.73 m$^2$] or serum Cr $>3$ mg/dL; difficulty in swallowing or inability to stand/sit upright for at least 30 min; and pregnancy or breastfeeding. The patients did not receive alendronate before the first DXA results were obtained. The patients were instructed to take the drug only upon getting up for the day, with 3–4 swallows of water; then fast for 30–45 min while standing, sitting, or walking; and finally eat breakfast. They were not to lie down or recline after taking the drug. Supplements or other drugs should be taken no sooner than 30 min after alendronate.

Immunosuppression Protocol

Our hospital primarily uses a calcineurin inhibitor (CI)–based immunosuppressive regimen in the initial months after transplantation. Most of our patients also receive mycophenolic acid plus prednisolone during this stage. Immediately after transplantation, the targeted cyclosporine concentration at 2 h post-dose ($C_2$) is approximately 1300–1100 ng/mL, and the tacrolimus trough level is maintained at approximately 12–10 ng/mL. These concentrations are gradually tapered in the first year. In patients that have had a transplant for more than 12 months, the cyclosporine $C_2$ level is maintained at approximately 500–600 ng/mL and the tacrolimus level at 3–4 ng/mL. Prednisolone is maintained at 1.25–10.00 mg per day, according to the patient’s condition. An mTOR inhibitor is added to the regimen if the patient’s condition is suitable (proteinuria $<800$ mg/day and eGFR $>40$ mL/[min·1.73 m$^2$]). The trough level of the mTOR inhibitor is maintained at approximately 3–8 ng/mL. Once the mTOR inhibitor has been added the CI and mycophenolic acid doses are cut by 50% overnight, while prednisolone is maintained at the same dosage. Subsequently, the CI dose is tapered as much as possible. Most of the patients in this study received only 25 mg cyclosporine or 0.5 mg tacrolimus per day if an mTOR inhibitor was used.

Statistical Analysis

Values of variables with non-normal distributions are presented as medians and interquartile ranges; data for variables with normal distributions are expressed as means ± SDs. Paired $t$ test and Wilcoxon signed rank test were used to compare baseline and follow-up data. Groups were compared using the Mann–Whitney test and $t$ test. Initially, simple linear regression analysis was used to identify immunosuppressive agents and biochemical and demographic variables associated with BMD change. The following factors were investigated: age, sex, time since transplantation, age at transplantation, use of prednisolone, use of mycophenolate, use of tacrolimus, use of sirolimus, use of cyclosporine, smoking habits, alcohol consumption, HBV infection, HCV infection, and CMV infection. Multiple linear regression analysis (stepwise forward approach) was then applied to assess predictors of BMD change. To calculate the relative risk of BMD change, standardized coefficients ($\beta$ and 95% confidence intervals (CIs) were obtained by linear regression analysis. All the nominal variables in linear regression were dummy coding transformed. The chi-squared test was used to determine the correlation between 2 binary variables; a $p$ value $<0.05$ was considered statistically significant. All statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS), version 12.0 for Windows (SPSS, Inc.; Chicago, IL, USA). Because of the exploratory nature of the study and the consequent lack of priori knowledge about effective size, no formal sample size computations were performed. F test was used to calculate post hoc power in this study. In the study of 76 patients of sample size, an effective size of 0.15 and an $\alpha$ of 0.05, the study power is 0.849. Post hoc power was calculated using G* power 3.0.
Results

Characteristics of the Study Sample

After a follow-up period of 14±1.6 months, 76 subjects underwent a second BMD assessment. Basic characteristics are summarized in Table 1 and 2. Among these subjects, 12 had a medical history of DM; 10 were infected with HBV, 15 with HCV, and 13 with CMV; 10 men were habitual users of tobacco; and 8 men and 1 woman regularly consumed alcohol. Thirty-four patients received alendronate, 57 prednisolone, 55 mycophenolate, 30 tacrolimus, 26 cyclosporine, and 34 sirolimus. A single immunosuppressive agent was administered to 8 (11%) patients; 21 (28%) patients received 2 immunosuppressive agents, 36 (47%) received 3, and 11 (14%) received 4. Of the 42 non–alendronate users, 9 had HCV infection; and 6 of the 34 alendronate users had HCV infection (Table 3).

Bone Mineral Density at Baseline and Follow-up

Table 3 presents the changes in BMD and blood biochemistry after 14±1.6 months of follow-up in patients who did and did not use alendronate. In the 42 non–alendronate users, serum albumin level decreased from 4.46±0.31 g/L to 4.37±0.40 g/L (p = 0.02). However, BMD of the lumbar spine increased from 0.96±0.13 g/cm² to 0.97±0.14 g/cm² (p = 0.007). The number of patients with osteoporosis increased from 7 to 12. In the 34 alendronate users, total cholesterol level decreased from 210±47 mg/dL to 194±40 mg/dL (p = 0.030), and BMD of the lumbar spine increased from 0.82±0.11 g/cm² to 0.86±0.12 g/cm² (p < 0.001). The number with osteoporosis decreased from 34 to 13. There was no significant change in bone mineral density of the hip bone or femoral neck in either group. No correlation between use of alendronate and use of immunosuppressive agents was found with chi-square test (p > 0.05).

Table 1. Baseline characteristics of 76 patients.

| Variable             | n   |
|----------------------|-----|
| Male sex             | 36  |
| Smoking              | 10  |
| Alcohol              | 9   |
| DM                   | 12  |
| HBV                  | 10  |
| HCV                  | 15  |
| CMV                  | 13  |
| Use of prednisolone  | 57  |
| Use of mycophenolate | 55  |
| Use of tacrolimus    | 30  |
| Use of cyclosporine  | 26  |
| Use of sirolimus     | 34  |
| Use of alendronate sodium | 34 |
| 1 immunosuppressive agent | 8   |
| 2 combined immunosuppressive agents | 21  |
| 3 combined immunosuppressive agents | 36  |
| 4 combined immunosuppressive agents | 11  |

Abbreviations: n, number of patients; CMV, cytomegalovirus; DM, diabetes mellitus; HBV, hepatitis B virus; HCV, hepatitis C virus.

Table 2. Laboratory results at baseline and at follow-up (N = 76).

| Parameter          | Baseline | Follow-up | p    |
|--------------------|----------|-----------|------|
| LS-BMD (g/cm²)     | 0.90±0.14| 0.92±0.14| <0.001|
| H-BMD (g/cm²)      | 0.81±0.14| 0.81±0.14| NS   |
| FN-BMD (g/cm²)     | 0.68±0.12| 0.69±0.13| NS   |
| LS T               | −1.53±1.24| −1.32±1.26| <0.001|
| H T                | −1.76±0.97| −1.68±1.07| NS   |
| FN T               | −2.45±0.96| −2.42±1.02| NS   |
| BUN (mg/dL)        | 19.7±10.0| 19.8±10.9| NS   |
| Cr (mg/dL)         | 1.18±0.54| 1.20±0.54| NS   |
| C-Ca (mg/dL)       | 9.11±0.47| 9.01±0.47| 0.01 |
| P (mg/dL)          | 3.21±0.54| 3.23±0.59| NS   |
| Uric acid (mg/dL)  | 6.24±1.68| 6.45±1.70| NS   |
| Albumin (g/L)      | 4.42±0.29| 4.34±0.40| 0.009|
| TC (mg/dL)         | 201±44   | 190±46   | 0.044|
| TM (mg/dL)         | 147±82   | 148±113  | NS   |
| Normal BMD         | 5        | 5        |      |
| Osteopenia         | 30       | 29       |      |
| Osteoporosis       | 41       | 42       |      |

Abbreviations: BMD, bone mineral density; BUN, blood urea nitrogen; C-Ca, serum corrected calcium; CMV, cytomegalovirus; Cr, blood creatinine; DM, diabetes mellitus; HCV, hepatitis C virus; FN, femoral neck; H, hip; LS, lumbar spine; NS, not significant (p > 0.05); P, serum inorganic phosphate; T, number of standard deviations above or below the mean value of BMD for sex-matched young adults; TC, serum total cholesterol; TG, serum triglyceride. LS-BMD was significantly greater at follow-up than at baseline. The albumin and calcium levels also decreased significantly, but they remained within normal ranges.

doi:10.1371/journal.pone.0063263.t002

Factors Associated with Bone Turnover in the Presence or Absence of Alendronate

We performed subgroup analysis to clarify the difference between patients who did and did not take alendronate and showed the difference values in table 3. The alendronate users had greater increase in lumbar spine BMD than the non–alendronate patients (0.035 [0.016, 0.052] g/cm² vs. 0.009 [−0.0032, 0.036] g/cm²; p = 0.002). The cumulative dose of prednisolone was significantly greater in the alendronate group (1450 mg ± 984.5 mg vs. 735 ± 699 mg, p = 0.001). Cumulative doses of other immunosuppressive agents were not different between alendronate patients and non–alendronate patients (p > 0.05). Age (49 y ± 9.1 y vs. 52.7 y ± 8.7 y), male sex (52.4% vs. 41.2%), HCV infection (22.5% vs. 18.8%), HBV infection (9.8% vs. 17.6%), CMV infection (17.5% vs. 18.8%), creatinine change (0.005 [−0.05, 0.142] mg/dL vs. 0.015 [−0.082, 0.162] mg/dL), serum albumin change (−0.06 [−0.225, 0.075] g/L vs. −0.02 [−0.215, 0.15] g/L), hip bone BMD change (−0.0005 [−0.021, 0.019] g/cm² vs. 0.018 [−0.011, 0.034] g/cm²), and femoral neck BMD change (0 [−0.022, 0.021] g/cm² vs. 0.025 [−0.022, 0.021] g/cm²) were not significantly different (p > 0.05) between alendronate and non-alendronate patients.

Factors Associated with Bone Turnover in the 76 Patients

In order to investigate the clinical features on bone condition, we used simple linear regression to evaluate associations between BMD change in the lumbar spine, hip bone, and femoral neck and the other clinical variables in 76 patients (table 4). Use of
alendronate (β = 0.345, 95% CI, 0.007 to 0.033; p = 0.002) and HCV infection (β = -0.262, 95% CI, -0.037 to -0.002; p = 0.027) were associated in patients with BMD change in the hip bone. Time since transplantation (β = -0.027, 95% CI, -0.0002 to -0.0001; p = 0.018) was associated in patients with BMD change in Hip bone. Age (β = -0.423, 95% CI, -0.003 to -0.001; p < 0.001) and age at transplant (β = -0.373, 95% CI, -0.003 to -0.001; p = 0.001) were associated in patients with BMD change in the femoral neck. In advanced multiple linear regression in 76 patients, HCV infection (β = -0.247, 95% CI, -0.033 to -0.002, p = 0.028) and use of alendronate (β = 0.37, 95% CI, 0.009 to 0.036, p = 0.001) were the significant risk factors with BMD change of lumbar spine; time since transplantation (β = -0.293, 95% CI, -0.0002 to -0.0001, p = 0.011) and use of alendronate (β = 0.246, 95% CI, 0.001 to 0.033, p = 0.035) were the significant risk factors with BMD change of hip bone and age (β = -0.464, 95% CI, -0.003 to -0.001, p < 0.001) was the significant risk factor with BMD change of femoral neck.

From the result of table 4, HCV infection was the significant risk factors with BMD change of lumbar spine but not in hip bone and femoral neck. To further our investigation of the influence of clinical features on bone condition between without and with alendronate patients, we used simple linear regression to evaluate other clinical variables in the alendronate and non-alendronate patients. At follow-up, LS-BMD was significantly increased in the alendronate and non-alendronate groups (p < 0.005). The albumin levels also decreased significantly in patients not taking alendronate sodium, but they remained within normal ranges. The uric acid and creatinine levels were significantly increased at follow-up in patients not taking alendronate sodium, but these also remained within normal ranges.

Table 3. Baseline and follow-up data for non-alendronate and alendronate patients.

| Parameter          | Non-alendronate (n = 42) | Alendronate (n = 34) |
|--------------------|--------------------------|----------------------|
|                    | Baseline | Follow-up | p     | Baseline | Follow-up | p     | P |
| LS-BMD (g/cm²)     | 0.96±0.13 | 0.97±0.14 | 0.007 | 0.82±0.11 | 0.86±0.12 | <0.001 | 0.002 |
| H-BMD (g/cm²)      | 0.87±0.13 | 0.87±0.14 | NS    | 0.72±0.10 | 0.73±0.10 | NS    | NS²    |
| FN-BMD (g/cm²)     | 0.74±0.11 | 0.75±0.12 | NS    | 0.60±0.05 | 0.60±0.06 | NS    | NS²    |
| LS T               | -1.01±1.15 | -0.86±1.24 | NS    | -2.15±1.04 | -1.87±1.06 | <0.001 |
| H T                | -1.27±0.80 | -1.22±0.97 | NS    | -2.35±0.82 | -2.24±0.90 | NS    |
| FN T               | -1.89±0.90 | -1.86±0.99 | NS    | -3.12±0.44 | -3.08±0.54 | NS    |
| Age (y)            | 49±9.1   | 52.7±8.7  | NS²   |
| Male sex           | 22/42    | 14/34     | NS²   |
| Smoking            | 6/42     | 4/34      | NS²   |
| Alcohol            | 6/42     | 3/34      | NS²   |
| DM                 | 10/42    | 2/34      | NS²   |
| HBV                | 4/42     | 6/34      | NS²   |
| HCV                | 9/42     | 6/34      | NS²   |
| CMV                | 7/42     | 6/34      | NS²   |
| BUN (mg/dL)        | 17.7±7.6 | 17.8±6.5  | NS    | 21.94±12.33 | 22.1±14.3 | NS    | NS³    |
| Cr (mg/dL)         | 1.08±0.41 | 1.14±0.38 | 0.034 | 1.27±0.64 | 1.31±0.67 | NS    | NS³    |
| C-Ca (mg/dL)       | 9.13±0.46 | 9.04±0.49 | NS    | 9.1±0.48  | 9.0±0.41  | NS    | NS³    |
| P (mg/dL)          | 3.19±0.58 | 3.19±0.58 | NS    | 3.23±0.49 | 3.27±0.6  | NS    | NS³    |
| Uric acid (mg/dL)  | 5.94±1.63 | 6.5±1.70  | 0.036 | 6.64±1.74 | 6.36±1.64 | NS    | NS³    |
| Albumin (g/L)      | 4.46±0.31 | 4.37±0.40 | 0.02  | 4.37±0.26 | 4.30±0.40 | NS    | NS³    |
| TC (mg/dL)         | 194±40   | 185±50    | NS    | 210±47    | 194±40    | 0.038 | NS³    |
| TG (mg/dL)         | 149±83   | 143±99    | NS    | 146±82    | 154±128   | NS    | NS³    |
| Normal BMD         | 5        | 5         | 0     | 4        |
| Osteopenia         | 30       | 25        | 0     | 4        |
| Osteoporosis       | 7        | 12        | 34    | 30       |
| Use of prednisolone| 66.7%    |           | 85.3% | NS²      |
| Use of mycophenolate| 73.8%  |           | 70.6% | NS²      |
| Use of tacrolimus  | 33.3%    |           | 47.1% | NS²      |
| Use of sirolimus   | 52.4%    |           | 35.3% | NS²      |
| Use of cyclosporine| 33.3%    |           | 35.3% | NS²      |

Abbreviations: BMD, bone mineral density; BUN, blood urea nitrogen; C-Ca, serum corrected calcium; Cr, blood creatinine; CMV, cytomegalovirus; DM, diabetes mellitus; FN, femoral neck; H, hip; HBV, hepatitis B virus; HCV, hepatitis C virus; LS, lumbar spine; NS, not significant (p > 0.05); P-S, serum inorganic phosphate; T, number of standard deviations above or below mean BMD of sex-matched young adults; TC, serum total cholesterol; TG, serum triglyceride. NS*, no significance (p > 0.05) between non-alendronate patients and alendronate patients. NS³, no significance (p > 0.05) of difference values between non-alendronate patients and alendronate patients. At follow-up, LS-BMD was significantly increased in the alendronate and non-alendronate groups (p < 0.005). The albumin levels also decreased significantly in patients not taking alendronate sodium, but they remained within normal ranges. The uric acid and creatinine levels were significantly increased at follow-up in patients not taking alendronate sodium, but these also remained within normal ranges.

doi:10.1371/journal.pone.0063263.t003
### Table 4. Clinical variables associated with bone mineral density change (N = 76).

| Variable                  | Lumbar Spine | Hip Bone | Femoral Neck | Hip Bone | Femoral Neck |
|---------------------------|--------------|----------|--------------|----------|--------------|
|                           | Simple $\beta$ (95% CI) | $p$ | Multiple $\beta$ (95% CI) | $p$ | Simple $\beta$ (95% CI) | $p$ | Multiple $\beta$ (95% CI) | $p$ |
| Age                       | 0.16 (−0.001, 0.001) | NS | −0.072 (−0.001, 0.001) | NS | −0.423 (−0.003, −0.001) | <0.001 | −0.464 (−0.003, −0.001) | <0.001 |
| Male sex                  | 0.093 (−0.008, 0.019) | NS | 0.0001 (−0.016, 0.016) | NS | 0.15 (−0.007, 0.032) | NS | 0.0001 (−0.016, 0.016) | NS |
| DM                        | −0.067 (−0.025, 0.016) | NS | −0.213 (−0.041, 0.002) | NS | −0.014 (−0.029, 0.026) | NS | −0.014 (−0.029, 0.026) | NS |
| HBV                       | 0.14 (−0.008, 0.032) | NS | 0.018 (−0.022, 0.025) | NS | −0.027 (−0.032, 0.026) | NS | −0.027 (−0.032, 0.026) | NS |
| HCV                       | −0.262 (−0.037, −0.002) | 0.027 | −0.247 (−0.035, −0.002) | 0.028 | −0.197 (−0.037, 0.003) | NS | −0.018 (−0.028, 0.024) | NS |
| CMV                       | −0.102 (−0.026, 0.011) | NS | −0.025 (−0.023, 0.019) | NS | −0.056 (−0.033, 0.020) | NS | −0.056 (−0.033, 0.020) | NS |
| Smoking                   | 0.043 (−0.017, 0.024) | NS | −0.054 (−0.029, 0.018) | NS | −0.023 (−0.032, 0.027) | NS | −0.023 (−0.032, 0.027) | NS |
| Alcohol                   | −0.023 (−0.023, 0.019) | NS | 0.039 (−0.021, 0.029) | NS | 0.066 (−0.022, 0.039) | NS | 0.066 (−0.022, 0.039) | NS |
| Time since transplantation | −0.061 (−0.001, 0.001) | NS | −0.275 (−0.0002, −0.0001) | 0.018 | −0.293 (−0.0002, −0.0001) | 0.011 | −0.037 (−0.001, 0.0001) | NS |
| Age at transplantation    | 0.198 (−0.001, 0.001) | NS | 0.078 (−0.001, 0.001) | NS | 0.373 (−0.003, −0.001) | 0.001 | 0.373 (−0.003, −0.001) | 0.001 |
| Prednisolone              | 0.085 (−0.01, 0.021) | NS | −0.012 (−0.019, 0.017) | NS | −0.036 (−0.026, 0.019) | NS | −0.036 (−0.026, 0.019) | NS |
| Mycophenolate             | −0.028 (−0.017, 0.013) | NS | −0.021 (−0.019, 0.016) | NS | 0.07 (−0.015, 0.028) | NS | 0.07 (−0.015, 0.028) | NS |
| Tacrolimus                | 0.138 (−0.006, 0.022) | NS | 0.163 (−0.005, 0.027) | NS | −0.075 (−0.027, 0.014) | NS | −0.075 (−0.027, 0.014) | NS |
| Sirolimus                 | −0.055 (−0.017, 0.01) | NS | 0.047 (−0.013, 0.019) | NS | 0.098 (−0.011, 0.028) | NS | 0.098 (−0.011, 0.028) | NS |
| Cyclosporine              | −0.081 (−0.002, 0.009) | NS | −0.132 (−0.006, 0.007) | NS | −0.05 (−0.025, 0.016) | NS | −0.05 (−0.025, 0.016) | NS |
| Alendronate               | 0.345 (0.007, 0.033) | 0.002 | 0.37 (0.009, 0.036) | 0.001 | 0.197 (−0.002, 0.029) | NS | 0.246 (0.001, 0.033) | 0.035 |

Abbreviations: CMV, cytomegalovirus; DM, diabetes mellitus; HBV, hepatitis B virus; HCV, hepatitis C virus; NS, not significant ($p > 0.05$). Initially, simple linear regression analysis was performed to identify the variables associated with bone mineral density (BMD) change in 76 patients. HCV infection and use of alendronate were associated with BMD change of the lumbar spine. Time since transplantation and use of alendronate were associated with BMD change of the hip bone. Age and age at transplantation were associated with BMD change of the femoral neck. In advanced analysis by multiple linear regression, HCV infection was still the risk factor for adverse BMD change of the lumbar spine. $\beta$ (95% CI): Linear regression standardized coefficients (95% confidence intervals).

doi:10.1371/journal.pone.0063263.t004
patients taking alendronate sodium (n = 34), age at transplantation (β: 0.379, 95% CI: 0.002, p = 0.03) showed an association in patients with BMD change in the lumbar spine. In advanced multiple linear regression, in non-alendronate patients (n = 42), HCV infection was the significant risk factor with BMD change of lumbar spine (β: −0.371, 95% CI: −0.044 to −0.004, p = 0.023). Otherwise, in patients with alendronate sodium (n = 34), no clinical was the significant risk factor with BMD change of lumbar spine.

Discussion

In this study, we showed that HCV infection was a risk factor for adverse BMD change in renal transplantation patients, especially in the lumbar spine. The negative effect of BMD change associated with HCV infection could be eliminated by using alendronate.

HCV infection is still highly prevalent among renal transplant recipients in both developed and developing countries [1,2]. The natural history of HCV infection after renal transplantation is still unclear [1]. Most studies of HCV infection in renal transplant recipients [17–19] have focused on mortality, graft survival, treatment response, and liver condition. Discussion of the correlation between HCV infection and bone condition in renal transplant recipients is limited. In this study, we showed that HCV infection was a risk factor for BMD change, especially in the lumbar spine, in renal transplant recipients.

It is well known that in renal transplant recipients, increase in bone mass loss is multifactorial and is affected by age [20], sex [20–22], renal function, and duration of dialysis before transplantation [22]. A major, well-known cause of increased loss of bone mass is high-dose steroid therapy during the early period after transplantation and long-term steroid administration [23]. In a previous cross-sectional study [13], renal transplant recipients with HCV infection had high prevalence rates of osteoporosis and osteopenia. In the general population, lower bone mineral density has been associated with chronic liver disease, including chronic viral hepatitis [5], but there was no correlation between severity of liver disease and bone density [24]. In the Mayo Clinic studies of BMD in more than 200 patients with advanced cirrhosis, 37% of the HCV-positive patients had osteopenia and 28% had osteoporosis. The percentage with osteoporosis was significantly higher in the HCV group than in the alcoholic liver disease (ALD) group, whereas the ALD group had more-advanced liver disease [25]. Another study comparing patients with HCV cirrhosis to those with ALD cirrhosis found that all patients with HCV infection had low bone density, while only half of the ALD group did [26].

Regarding osteoporosis caused by HCV, recent studies have focused on HIV/HCV co-infection [11,12,27,28]. Osteoporosis was very common in African-American patients with HIV/HCV co-infection [28]. Hansen et al. [27] also pointed out that the relative risk of fracture was higher in HIV/HCV co-infection patients than in HIV monoinfection patients. To our knowledge, HIV is the cause of a spectrum of disease known as HIV/AIDS. HIV is a retrovirus that primarily infects components of the human immune system, such as CD4+ T cells, macrophages, and dendritic cells. It directly and indirectly destroys CD4+ T cells [29]. The mechanism by which HIV/HCV co-infection aggravates BMD change is still not clearly understood. Immunosuppressive agents prescribed for transplant recipients affect T-cell activation and subsequent cellular proliferation. These findings indicate that patients with HIV and transplant recipients taking immunosuppressive agents have a similar condition. To our knowledge, studies of bone condition in renal transplant recipients

| Variable | No Alendronate | Alendronate |
|----------|---------------|-------------|
|          | Simple β (95% CI) | p   | Multiple β (95% CI) | p   | Simple β (95% CI) | p   | Multiple β (95% CI) | p   |
| Age      | −0.072 (−0.001, 0.001) | NS  | −0.004 | NS  | 0.276 (0.002) | NS  | −           | −   |
| Male sex | 0.158 (−0.009, 0.026) | NS  | 0.118 | NS  | 0.16 (−0.011, 0.029) | NS  | −           | −   |
| DM       | −0.067 (−0.025, 0.016) | NS  | −0.149 | NS  | 0.066 (−0.027, 0.026) | NS  | −           | −   |
| HBV      | 0.21 (−0.01, 0.047) | NS  | 0.218 | NS  | −           | −   | −           | −   |
| HCV      | −0.36 (−0.043, −0.003) | 0.023 | 0.371 (−0.043, −0.003) | 0.023 | 0.043 (−0.03, 0.024) | NS  | −           | −   |
| CMV      | 0.013 (−0.022, 0.024) | NS  | 0.087 | NS  | 0.28% (−0.046, 0.005) | NS  | −           | −   |
| Smoking  | 0.081 (−0.019, 0.031) | NS  | 0.148 | NS  | 0.016 (−0.03, 0.033) | NS  | −           | −   |
| Alcohol  | 0.081 (−0.019, 0.031) | NS  | 0.148 | NS  | 0.118% (−0.047, 0.024) | NS  | −           | −   |
| Time since transplantation | −0.055 (−0.009, 0.0001) | NS  | 0.074 | NS  | 0.237% (−0.009, 0.001) | NS  | −           | −   |
| Age at transplantation | −0.023% (−0.001, 0.0001) | NS  | −0.038 | NS  | 0.379 (0.002) | 0.03 | −           | −   |
| Prednisolone | 0.165 (−0.009, 0.028) | NS  | 0.157 | NS  | −0.21% (−0.046, 0.01) | NS  | −           | −   |
| Mycophenolate | 0.004 (−0.02, 0.02) | NS  | −0.097 | NS  | −0.017 (−0.023, 0.021) | NS  | −           | −   |
| Tacrolimus | 0.018 (−0.018, 0.02) | NS  | 0.021 | NS  | 0.151 (−0.011, 0.028) | NS  | −           | −   |
| Sirolimus | 0.093 (−0.012, 0.023) | NS  | −0.052 | NS  | −0.138% (−0.029, 0.013) | NS  | −           | −   |
| Cyclosporine | −0.178 (−0.029, 0.008) | NS  | −0.034 | NS  | 0.06% (−0.017, 0.024) | NS  | −           | −   |

Abbreviations: CMV, cytomegalovirus infection; DM, diabetes mellitus; HBV, hepatitis B virus infection; HCV, hepatitis C virus infection; NS, not significant (p > 0.05). Initially, simple linear regression analysis was performed to identify the variables associated with BMD change in patients taking alendronate sodium and those who were not. HCV infection was negatively associated with BMD change of the lumbar spine in patients not taking alendronate. Age at transplantation was positively associated with BMD change in the lumbar spine in patients taking alendronate. In advanced analysis by multiple linear regression, HCV infection was still the risk factor for adverse BMD change of the lumbar spine in patients not taking alendronate. No clinical variable was a risk factor for predicting BMD change of the lumbar spine in patients taking alendronate. β (95% CI): Linear regression standardized coefficients (95% confidence intervals).

doi:10.1371/journal.pone.0063263.t005
with HCV infection are rare. It seems that HCV infection in the presence of suppressed T-cell activity may have a role in BMD loss.

Recently, a cytokine system (including receptor activator of nuclear factor kappa-B [RANK], receptor activator of nuclear factor kappa-B ligand [RANKL], and osteoprotegerin [OPG]) [30–32] was found to regulate the proliferation, differentiation, and apoptosis of osteoclasts [33–35]. Several tissues produce RANKL, especially lymphoid tissues and bone [30–32,36,37]. Osteoporosis caused by portosystemic shunting [38], or by steroid or CIs through receptor activator of RANKL-dependent pathways, may be partially ameliorated using sirolimus [39]. Recently, serum levels of soluble RANKL were measured in patients with chronic liver disease. Szalay et al. [40] showed that patients with primary biliary cirrhosis tended to have high OPG and low RANKL levels, and patients with chronic HCV infection exhibited high OPG and RANKL levels. Moschen et al. [41] demonstrated high OPG and RANKL levels in patients with liver disease but without cirrhosis, including those with alcoholic hepatitis, primary biliary cirrhosis, and viral hepatitis. Another study [42] showed that patients with alcoholic cirrhosis had high OPG and RANKL levels.

It is worth to note that in our study, HCV infection had a negative role of BMD change of the lumbar spine. However, in hip bone and femoral neck, the role of HCV infection was not found.

In our knowledge, vertebrae consist of about 50% trabecular bone, while other bones (hip, femoral neck and trochanter) consist mainly of cortical bone [43]. In clinical study by George el al [26], among the 79 chronic liver disease patients, 49 had low BMD and lumbar spine was the most frequently and severely affected site. All of the patients with HCV infection had low BMD. In addition, in a study on osteoporosis in patients with end-stage liver disease caused by hepatitis C and ALD, Carey et al. [25] showed that hepatitis C patients had the lowest lumbar bone density and ALD patients had the highest bone density. In a prospective cohort study [28], El-Maouche et al. showed that osteoporosis was very common in the lumbar spine among the African-American patients with HIV/HCV co-infection. It is unclear about the mechanism between HCV infection and bone loss of lumbar spine. However, from above cited references, it may be explained that sites with a high proportion of trabecular bone are affected earliest in diseases like HCV infection that produce increased bone turnover.

Previously, vitamin D status was assessed in patients with noncholestatic chronic liver diseases [44]. Some studies [45,46] showed that HCV infection may reduce vitamin D levels. About 70% of non-cirrhotic HCV-positive patients had 25(OH)D levels (<20 ng/mL), and 14% had 25(OH)D severe deficiency (<7 ng/mL) [44]. Vitamin D deficiency, secondary hyperparathyroidism, and osteoporosis often coexist in elderly women [47–49]. In a randomized, controlled study, Barone et al. pointed out that elderly women with osteoporosis caused due to hypovitaminosis D had a good response to alendronate [50]. Another study found no significant difference in BMD response to treatment in vitamin D-replete compared to vitamin D-deficient postmenopausal women who were taking bisphosphonates [51]. Based on these references, we can explain why HCV was not a risk factor for BMD change in our 34 alendronate patients. Further, it seems that alendronate may be able to reverse bone lesions in renal transplant recipients with HCV infection.

Although the limitations of our study (its retrospective design and small sample) are evident, to our knowledge, these are the first reported data showing the effect of HCV infection on bone in renal transplant patients and indicating that alendronate can counteract this negative effect.

Conclusion

This randomized case-control study has shown that HCV infection in renal transplant recipients was a risk factor for adverse BMD change of the lumbar spine. Moreover, alendronate may be able to reverse bone lesions in renal transplant recipients with HCV infection.

Acknowledgments

We thank the members of the Immune Transplant Center at Chang Gung Memorial Hospital for their invaluable and dedicated assistance.

Author Contributions

Conceived and designed the experiments: WH PL. Performed the experiments: WH MY PL. Analyzed the data: WH MY JH. Contributed reagents/materials/analysis tools: WH JH. Wrote the paper: WH PL.

References

1. Fabrizi F, Poordad FF, Martin P (2002) Hepatitis C infection and the patient with end-stage renal disease. Hepatology 36: 3–10.
2. Vosmides GG (1997) Hepatitis C in renal transplantation. Kidney Int 52: 843–861.
3. Periera BJ, Wright TL, Schmid CH, Levey AS (1995) The impact of pretransplantation hepatitis C infection on the outcome of renal transplantation. Transplantation 60: 799–805.
4. Roth D. (1995) Hepatitis C virus; the nephrologist’s view. Am J Kidney Dis 25: 3–16.
5. Bruchfeld A, Wilczek H, Elinder CG (2004) Hepatitis C infection, time in renal-replacement therapy, and outcome after kidney transplantation. Transplantation 78: 745–750.
6. Morales JM, Dominguez-Gil B, Sanz-Guajardo D, Fernandez J, Escuin F (2004) The influence of hepatitis B and hepatitis C virus infection in the recipient on late renal allograft failure. Nephrol Dial Transplant 19: Suppl 6.
7. Miwali AH, Alam A, Al-Waked J, Al Sawadha K, Tarif N, et al. (2006) Effect of chronic viral hepatitis on graft survival in Saudi renal transplant patients. Nephron Clin Pract 102: c72–80.
8. Hay JE, Guelcheran MM (2005) Evaluation and management of osteoporosis in liver disease. Clin Liver Dis 9: 747–766.
9. Arase Y, Suzuki F, Suzuki Y, Akuta N, Kobayashi M, et al. (2010) Virus clearance reduces bone fracture in postmenopausal women with osteoporosis and chronic liver disease caused by hepatitis C virus. J Med Virol 82: 390–395.
10. Schiefer I, Fach A, Wiedmann M, Arenin AV, Schenker E, et al. (2005) Reduced bone mineral density and altered bone turnover markers in patients with non-cirrhotic chronic hepatitis B or C infection. World J Gastroenterol 11: 1843–1847.
11. Collin F, Duvat X, Le M, V, Piroth L, Al KF, et al. (2009) Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV-infected adults. AIDS 23: 1021–1029.
12. Young B, Dao CN, Buchacz K, Baker R, Brooks JT (2011) Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000–2006. Clin Infect Dis 552: 1061–1068.
13. Huang WH, Lai PC (2011) Age at transplant—one of the factors affecting bone mineral density in kidney recipients—a single-center retrospective study. Ren Fail 33: 776–780.
14. Von EE, Ahman DG, Egger M, Pocock SJ, Gotzsche PC, et al. (2007) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med 4: e296.
15. Huang WH, Lee SY, Weng CH, Lai PC (2012) Use of alendronate sodium (fosamax) to ameliorate osteoporosis in renal transplant patients: a case-control study. PLoS ONE 7: e48481.
16. Liu SH, Lin JL, Weng CH, Yang HY, Hsu CW, et al. (2012) Heart rate-corrected QT interval helps predict mortality after intentional organophosphate poisoning. PLoS ONE 7: e56516.
17. Fabrizi F, Martin P, Dichi V, Bunnapradist S, Dula G (2005) Hepatitis C virus antibody status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant 3: 1452–1461.
18. Rostami Z, Noushraba MH, Alavian SM, Bierasphlar F, Jahani Y, et al. (2011) The impact of Hepatitis C virus infection on kidney transplantation outcomes: a systematic review of 18 observational studies: The impact of HCV on renal transplantation. Hepat Mon 11: 247–254.
19. Fabrizi F, Languin G, Discit V, Martin P (2006) Meta-analysis: anti-viral therapy of hepatitis C virus-related liver disease in renal transplant patients. Aliment Pharmacol Ther 24: 1143–1147.

20. Hung CJ, Lee PC, Song CM, Chang YT, Tsai MT, et al. (1996) Clinical implication of hormone treatment in postmenopausal kidney transplants. Transplant Proc 28: 1548–1550.

21. Kokado Y, Takahara S, Ichimaru N, Toki K, Kyo M, et al. (2000) Factors influencing vertebral bone density after renal transplantation. Transpl Int 13: Suppl 5.

22. Arditi A, Tarantino A, Montagutino G, Cesana B, Cocucci C, et al. (1997) Effects of three immunosuppressive regimens on vertebral bone density in renal transplant recipients: a prospective study. Transplantation 63: 309–308.

23. Kodras K, Haas M (2000) Effect of kidney transplantation on bone. Eur J Clin Invest 36: Suppl 75.

24. Loria I, Albanese C, Giusto M, Galteri PA, Giannelli V, et al. (2010) Bone disorders in patients with chronic liver disease awaiting liver transplantation. Transplant Proc 42: 1191–1193.

25. Carey EJ, Balan V, Kremers WK, Hay JE (2005) Osteopenia and osteoporosis in patients with end-stage liver disease caused by hepatitis C and alcoholic liver disease: not just a cholestatic problem. Liver Transpl 9: 1166–1173.

26. George J, Ganesh HK, Acharya S, Bandgar TR, Shivane V, et al. (2009) Bone mineral density and disorders of mineral metabolism in chronic liver disease. World J Gastroenterol 15: 3516–3522.

27. Hansen AB, Gerstoft J, Kronborg G, Larsen CS, Pedersen C, et al. (2012) Incidence of low and high-energy fractures in persons with and without HIV infection: a Danish population-based cohort study. AIDS 26: 205–293.

28. El-Maouche D, Mehta SH, Sutcliffe C, Higgins Y, Torbenson MS, et al. (2011) Bone mineral density and bone turnover in patients with chronic kidney disease: a Danish population-based cohort study. AIDS 26: 205–293.

29. Alimonti JB, Ball TB, Fowke KR (2003) Mechanisms of CD4+ T lymphocyte cell death in human immunodeficiency virus infection and AIDS. J Gen Virol 84: 7–61.

30. Wong BR, Rho J, Aron J, Robinson E, Orlinick J, et al. (1997) TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem 272: 25190–25194.

31. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, et al. (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95: 5997–6002.

32. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, et al. (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165–176.

33. Dunstan CR (2000) Osteoprotegerin and Osteoprotegerin Ligand Mediate the Local Regulation of Bone Resorption. Endocrinologist 10: 18–26.

34. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, et al. (1997) Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocrinology 138: 345–357.

35. Wong BR, Josien R, Chou Y (1999) TRANCE is a TNF family member that regulates dendritic cell and osteoclast function. J Leukoc Biol 65: 715–724.

36. Kartogianis V, Zhou H, Horwood NJ, Thomas RJ, Hardt DK, et al. (1999) Localization of RANKL (receptor activator of NF kappa B ligand): mRNA and protein in skeletal and extraskeletal tissues. Bone 25: 525–534.

37. Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, et al. (1995) A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 370: 173–179.

38. van der Merwe SW, Conradie MM, Bond R, Olivier BJ, Fritz E, et al. (2006) Effect of ranpirnacin on hepatic osteodystrophy in rats with portasystemic shunting. World J Gastroenterol 12: 4504–4510.

39. Westerfeld R, Schlieper G, Wolzle M, Gawlik A, Brandenburg V, et al. (2011) Impact of sirolimus, tacrolimus and mycophenolate mofetil on osteoclastogenesis-implications for post-transplantation bone disease. Nephrol Dial Transplant 26: 4115–4123.

40. Szalay F, Hegeduš L, Lakatos PL, Tornai I, Bajnok E, et al. (2003) High serum osteoprotegerin and low RANKL in primary biliary cirrhosis. J Hepatol 38: 395–400.

41. Mcchery AR, Kaser A, Stadlmann S, Miller K, Kaser S, et al. (2005) The RANKL/OPG system and bone mineral density in patients with chronic liver disease. J Hepatol 43: 973–983.

42. Fabrega E, Orive A, Garcia-Suarez C, Garcia-Urzueta M, Antonio AJ, et al. (2003) Osteoprotegerin and RANKL in alcoholic liver cirrhosis. Liver Int 25: 305–310.

43. Osteoporosis. Available at :http://en.wikipedia.org/wiki/Osteoporosis. Accessed Jan 16, 2013.

44. Gutierrez JA, Parikh N, Branch AD (2011) Classical and emerging roles of vitamin D in hepatitis C virus infection. Semin Liver Dis 31: 387–398.

45. Hepner GW, Rognoky M, Moom HF (1976) Abnormal vitamin D metabolism in patients with cirrhosis. Am J Dig Dis 21: 527–532.

46. Artch J, Narra S, Nair S (2010) Prevalence of vitamin D deficiency in chronic liver disease. Dig Dis Sci 55: 2624–2629.

47. Lips P (2001) Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev 22: 477–501.

48. von Mehlen DG, Greendale GA, Garland CF, Wan L, Barrett-Connor E (2005) Vitamin D, parathyroid hormone levels and bone mineral density in community-dwelling older women: the Rancho Bernardo Study. Osteoporos Int 16: 1721–1726.

49. Sugardson G, Franson L, Steingrimsson D, Sigvaldason H (2000) The association between parathyroid hormone, vitamin D and bone mineral density in 70-year-old Icelandic women. Osteoporos Int 11: 1031–1035.

50. Barone A, Giusti A, Poli G, Giraso A, Razzano M, et al. (2007) Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial. J Am Geriatr Soc 55: 752–757.

51. Deane A, Constancio L, Fogelman I, Hampson G (2007) The impact of vitamin D status on changes in bone mineral density during treatment with bisphosphonates and after discontinuation following long-term use in post-menopausal osteoporosis. BMC Musculoskelet Disord 8: 3.